Flag of the European Union EU Clinical Trials Register Help

Clinical trials for BCG

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    132 result(s) found for: BCG. Displaying page 2 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2020-002111-22 Sponsor Protocol Number: BCG/COVID-19/UR/04/2020 Start Date*: 2020-06-26
    Sponsor Name:University of Rzeszów
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in ...
    Medical condition: not applicable
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002781-12 Sponsor Protocol Number: 2019061567 Start Date*: 2021-08-05
    Sponsor Name:University of Southern Denmark, Bandim Health Project
    Full Title: Using BCG vaccine to strengthen the immune system in the elderly and improve the response to influenza vaccine. A randomized clinical trial.
    Medical condition: Immune response to seasonal influenza vaccine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    21.0 100000004848 10060063 Influenza serology LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000736-10 Sponsor Protocol Number: BCG-RIS-01 Start Date*: 2019-01-24
    Sponsor Name:FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS
    Full Title: “Bacille Calmette-Guérin (BCG) vaccine In Radiologically Isolated Syndrome (Ris)”
    Medical condition: Radiologically Isolated Syndrome (Ris)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10079292 Radiologically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003488-71 Sponsor Protocol Number: OVG-2013/04 Start Date*: 2013-12-12
    Sponsor Name:University of Oxford
    Full Title: A pilot study of the impact of BCG administration on the immunogenicity of serogroup C meningococcal conjugate vaccine in healthy infants
    Medical condition: Vaccine responses
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000182-33 Sponsor Protocol Number: 76421 Start Date*: 2021-03-25
    Sponsor Name:Radboudumc
    Full Title: Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers
    Medical condition: Immunogenicity of the mRNA BNT162b2 COVID-19 vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002448-21 Sponsor Protocol Number: ACTIVATEII Start Date*: 2020-05-26
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL
    Medical condition: Prevention of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036897 Prophylactic vaccination LLT
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002449-39 Sponsor Protocol Number: 42756493BLC2003 Start Date*: 2020-07-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Inva...
    Medical condition: Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) CZ (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003496-11 Sponsor Protocol Number: EN3348-303 Start Date*: 2012-02-08
    Sponsor Name:Endo Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared with Mitomycin C in the Intravesical Treatment of Subjects wi...
    Medical condition: BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001775-35 Sponsor Protocol Number: MC-BCG.4/HBCA Start Date*: 2007-07-12
    Sponsor Name:medac GmbH
    Full Title: Intravesical instillation of BCG strain RIVM versus TICE for prevention of recurrenec in patients with high-risk papillary superficial carcinomas of the urinary bladder. A randomised phase II clini...
    Medical condition: immunostimulating adjuvant therapy of superficial carcinomas of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046518 Urinary bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001888-90 Sponsor Protocol Number: 20201504 Start Date*: 2020-04-30
    Sponsor Name:University of Southern Denmark
    Full Title: Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial.
    Medical condition: Healthy volunteers, health care workers. Immune system activation after BCG vaccination. Work absenteeism and COVID-19 will be monitored.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004512-19 Sponsor Protocol Number: UC-0160/1717 Start Date*: 2018-10-09
    Sponsor Name:UNICANCER
    Full Title: An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-...
    Medical condition: High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010579-26 Sponsor Protocol Number: 2009-01 Start Date*: 2010-08-03
    Sponsor Name:Julio A Virseda Rodriguez
    Full Title: TRATAMIENTO INTRAVESICAL, EFECTO TERAPÉUTICO Y PREVENTIVO CON FÁRMACOS ANTINEOPLÁSICOS, MITOMICINA C EN UNA SOLA DOSIS ADMINISTRADOS EN LAS PRIMERAS 24 HORAS DE RESECCIÓN TRANSURETRAL DE VEJIGA SUP...
    Medical condition: Tratamiento adyuvante del cáncer superficial de vejiga
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001591-15 Sponsor Protocol Number: NL73430.091.20 Start Date*: 2020-04-09
    Sponsor Name:Radboudumc
    Full Title: Reducing hospital admission of elderly in SARS-CoV-2 pandemic via the induction of trained immunity by bacillus Calmette-Guérin vaccination, a randomized controlled trial.
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10047490 Virus identification and serology HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005330-58 Sponsor Protocol Number: SAKK06/14 Start Date*: 2016-08-22
    Sponsor Name:SAKK (Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung)
    Full Title: A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy
    Medical condition: Treatment of patients with recurrent non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003112-27 Sponsor Protocol Number: NORTH-REG-3 Start Date*: 2020-09-14
    Sponsor Name:Aarhus University [...]
    1. Aarhus University
    2.
    Full Title: Nordic Urothelial Cancer Research Group Study on Reduced BCG Dwell-Time in High Risk NMIBC Short title: NORTH-REG Dwell-Time Study
    Medical condition: Reduced BCG dwell time in patients who are diagnosed with high risk non-muscle-invasive- bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002100-13 Sponsor Protocol Number: ESR-16-12611 Start Date*: 2018-10-11
    Sponsor Name:Hellenic GenitoUrinaty Cancer Group (HGUCG)
    Full Title: Intravesical administration of Durvalumab (MEDI4736) to patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). A phase II study with correlative biomarker studies.
    Medical condition: Non-muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000150-22 Sponsor Protocol Number: T14/2018 Start Date*: 2018-06-05
    Sponsor Name:Turku University Hospital
    Full Title: Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive Mitomycin-C (EMDA-MCC) in patients with high risk non-muscle-invasive bladder carcinoma
    Medical condition: Non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004540-37 Sponsor Protocol Number: MITOBCG Start Date*: 2018-10-11
    Sponsor Name:AZIENDA OSPEDALIERA SANT'ANDREA
    Full Title: The effects of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer
    Medical condition: patients with High grade Non-Muscle Invasive Bladder Cancer with high progression risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038364 Renal and urinary tract neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001236-28 Sponsor Protocol Number: R39_21_01 Start Date*: 2023-01-13
    Sponsor Name:Fidia Farmaceutici S.p.A.
    Full Title: A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG-unresponsive Carcinoma in Si...
    Medical condition: BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007400 Carcinoma in situ of the bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004273-27 Sponsor Protocol Number: CUETO1801 Start Date*: 2019-04-08
    Sponsor Name:PRESURGY, S.
    Full Title: Multicenter clinical trial with medical device associated with a drug in an authorised therapeutic use for the treatment of CVNMI evaluating the efficacy and tolerability of the adyuvant treatment ...
    Medical condition: bladder cancer non muscle invasive in high risk patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10029759 Normal delivery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:41:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA